Market Research Industry Reports

Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2018

Summary

GlobalDatas clinical trial report, Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2018" provides an overview of Non-Hodgkin Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Hodgkin Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Non-Hodgkin Lymphoma Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Non-Hodgkin Lymphoma 30
Apr 04, 2018: Nordic Nanovector Provides Update on the Humalutin Clinical Development Program 30
Mar 15, 2018: Nordic Nanovector to Present Preclinical Data Highlighting the Anti-tumour Effect of Humalutin in Three Lymphoma Models at AACR 2018 30
Jan 17, 2018: Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma 30
Jan 16, 2018: Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma 31
Clinical Trial Profile Snapshots 32
Appendix 2408
Abbreviations 2408
Definitions 2408
Research Methodology 2409
Secondary Research 2409
About GlobalData 2410
Contact Us 2410
Disclaimer 2410
Source 2411

List Of Tables

List of Tables
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Region, 2018* 7
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 10
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 11
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2018* 12
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 13
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 14
Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2018* 15
Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2018* 18
Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19
Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2018* 21
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 22
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25
Non-Hodgkin Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 26
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 27
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 28
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 29

List Of Figures

List of Figures
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 10
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 11
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 12
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 13
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 14
Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2018* 15
Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2018* 18
Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19
Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2018* 21
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 22
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25
Non-Hodgkin Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 26
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 27
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 28
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 29
GlobalData Methodology 2409

Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2018

Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2018 provides an overview of Non-Hodgkin Lymphoma clinical trials scenario. This report

USD 2500View Report

Global Non-Hodgkin Lymphoma Partnering 2012 to 2018

Provides understanding and access to the non-hodgkin lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies.

USD 1995View Report

Global Non-Hodgkin Lymphoma Partnering 2012 to 2018

Provides understanding and access to the non-hodgkin lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies.

USD 1995View Report

B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2018

B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across B-Cell Non-Hodgkin Lymphoma development. The report

USD 1500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2500
  • Site Licence    USD 5000
  • Enterprise Wide Licence    USD 7500
$ 2500

Reports Details

Published Date : Mar 2018
No. of Pages :2411
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube